PROK
Price:
$1.69
Market Cap:
$492.99M
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.[Read more]
Industry
Biotechnology
IPO Date
2021-06-30
Stock Exchange
NASDAQ
Ticker
PROK
According to ProKidney Corp.’s latest financial reports and current stock price. The company's current PE Ratio is -3.13. This represents a change of -8.30% compared to the average of -3.41 of the last 4 quarters.
The mean historical PE Ratio of ProKidney Corp. over the last ten years is -23.98. The current -3.13 PE Ratio has changed 1.21% with respect to the historical average. Over the past ten years (40 quarters), PROK's PE Ratio was at its highest in in the September 2001 quarter at 0. The PE Ratio was at its lowest in in the June 2023 quarter at -19.81.
Average
-23.98
Median
-9.97
Minimum
-70.49
Maximum
-2.85
Discovering the peaks and valleys of ProKidney Corp. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 606.89%
Maximum Annual PE Ratio = -2.85
Minimum Annual Increase = -91.49%
Minimum Annual PE Ratio = -70.49
Year | PE Ratio | Change |
---|---|---|
2023 | -3.10 | 8.68% |
2022 | -2.85 | -91.49% |
2021 | -33.48 | -52.50% |
2020 | -70.49 | 606.89% |
The current PE Ratio of ProKidney Corp. (PROK) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-13.14
5-year avg
-23.98
10-year avg
-23.98
ProKidney Corp.’s PE Ratio is less than Relay Therapeutics, Inc. (-1.93), greater than Stoke Therapeutics, Inc. (-6.11), greater than Pliant Therapeutics, Inc. (-3.91), less than Black Diamond Therapeutics, Inc. (-1.96), greater than Arvinas, Inc. (-6.04), greater than Arcellx, Inc. (-120.42), less than Ventyx Biosciences, Inc. (-0.86), greater than Immunocore Holdings plc (-30.05), greater than Vaxcyte, Inc. (-21.57), greater than DICE Therapeutics, Inc. (-22.94), greater than Third Harmonic Bio, Inc. (-44.42), less than PMV Pharmaceuticals, Inc. (-1.61), greater than Edgewise Therapeutics, Inc. (-24.30), less than Enochian Biosciences, Inc. (-1.00), greater than Revolution Medicines, Inc. (-16.70), greater than Kura Oncology, Inc. (-4.75), less than Protagonist Therapeutics, Inc. (16.80), greater than Merus N.V. (-12.70), greater than Replimune Group, Inc. (-5.51), greater than Cerevel Therapeutics Holdings, Inc. (-17.73), greater than Monte Rosa Therapeutics, Inc. (-5.83), greater than Erasca, Inc. (-4.79), less than Lyell Immunopharma, Inc. (-1.19),
Company | PE Ratio | Market cap |
---|---|---|
-1.93 | $795.07M | |
-6.11 | $605.41M | |
-3.91 | $789.88M | |
-1.96 | $143.73M | |
-6.04 | $1.78B | |
-120.42 | $4.89B | |
-0.86 | $130.81M | |
-30.05 | $1.61B | |
-21.57 | $11.04B | |
-22.94 | $2.27B | |
-44.42 | $561.88M | |
-1.61 | $83.31M | |
-24.30 | $3.05B | |
-1.00 | $45.38M | |
-16.70 | $9.55B | |
-4.75 | $839.85M | |
16.80 | $2.77B | |
-12.70 | $3.11B | |
-5.51 | $1.02B | |
-17.73 | $8.19B | |
-5.83 | $521.60M | |
-4.79 | $763.36M | |
-1.19 | $265.26M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ProKidney Corp. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like ProKidney Corp. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is ProKidney Corp.'s PE Ratio?
How is the PE Ratio calculated for ProKidney Corp. (PROK)?
What is the highest PE Ratio for ProKidney Corp. (PROK)?
What is the 3-year average PE Ratio for ProKidney Corp. (PROK)?
What is the 5-year average PE Ratio for ProKidney Corp. (PROK)?
How does the current PE Ratio for ProKidney Corp. (PROK) compare to its historical average?